Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)
Updated: December 14, 2025 Eli Lilly and Company (NYSE: LLY) heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating pricing pressure. The stock’s most recent close (U.S. markets were shut Sunday) was $1,027.51. StockAnalysis Over the past two weeks, Lilly headlines have clustered around three catalysts that matter directly to the stock: Below is a detailed, publication-ready roundup of the key news, forecasts, and analyst takes driving Eli Lilly stock as of 14.12.2025. What’s moving Eli Lilly stock right